Investigating how the ARID1A gene affects cancer treatment and immune response
Official title: The Role of the Tumor Suppressor ARID1A in R loop Homeostasis and Tumor Immunity
Funded at Salk Institute for Biological Studies · NIH-11004104 · Data updated 2026-11-12
This study is looking at how changes in the ARID1A gene might affect how well certain cancer treatments that boost the immune system work, with the goal of helping doctors find better ways to treat cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $573,836 |
| NIH project number | 5R01CA285867-02 |
| Project ID | NIH-11004104 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients with mutations in the ARID1A gene who are undergoing or considering immune checkpoint blockade therapy.
✕Less likely to help
Patients without ARID1A mutations or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research focuses on understanding the role of the ARID1A gene in cancer immunotherapy, particularly how mutations in this gene may influence the effectiveness of treatments that activate the immune system against tumors. The study aims to explore the genetic and molecular factors that determine patient responses to immune checkpoint blockade (ICB), a type of therapy that enhances the activity of T cells to fight cancer. By examining the relationship between ARID1A mutations and ICB response, the research seeks to identify potential biomarkers that could improve treatment outcomes for cancer patients. The methodology includes analyzing genetic data from cancer patients and conducting experiments to understand the underlying mechanisms of ARID1A's role in tumor immunity.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment strategies that better utilize the immune system, potentially increasing the number of patients who benefit from immunotherapy.
How similar studies have gone: Previous studies have indicated that mutations in the ARID1A gene are associated with positive responses to immunotherapy, suggesting that this research builds on established findings in the field.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Hargreaves, Diana Clare — Salk Institute for Biological Studies
- Study coordinator: Hargreaves, Diana Clare
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.